ProMIS Neurosciences Secures Private Financing

ProMIS Neurosciences (PMN) entered into a purchase agreement with an existing institutional and accredited investor to issue and sell a total of approximately $2.4M in warrants. The Warrants were sold at a price of $0.1875 per share through a private investment in public equity transaction. The Warrants have an exercise price of $1.25 per Warrant Share, are immediately exercisable, and will expire five years from the date of initial issuance. The PIPE financing involved participation from an existing institutional investor focused on healthcare. ProMIS expects the gross proceeds from the PIPE financing to be approximately $2.4M, before subtracting fees and other expenses related to the offering. Along with the proceeds from the exercise of existing warrants, the total gross proceeds for the Company, including the PIPE Offering, are expected to be around $9.2M. The PIPE financing is anticipated to close on July 24, 2025, subject to standard closing conditions. The funds from the PIPE financing are intended to support the clinical development of PMN310, ProMIS’ primary therapeutic candidate, as well as for working capital and other general corporate purposes.

Elevate Your Investing Strategy:

• Take advantage of Premium at 50% off!Access strong investment tools, detailed information, and professional analyst recommendations to support your confident investing decisions.